Bottom line
RXL vs HCPIX: the short answer
RXL (ProShares Ultra Health Care) and HCPIX (Health Care Ultrasector Profund) share a meaningful slice of their top holdings — about 70% by weight.
RXL is cheaper at 0.95% vs 1.76% — a difference of $81 a year per $10,000 invested.
Over five years, RXL returned +7.2% a year vs +6.4% for HCPIX (reporting dates differ).
Updated Nov 19, 2026
RXL vs HCPIX side by side
| RXL | HCPIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | ProShares | ProShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.95% | 1.76% |
| Annual cost per $10k | $95 | $176 |
| 10-yr cost on $10k (prospectus) | $1,305 | $2,073 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +19.7% | −1.4% |
| 5-yr return (annualized) | +7.2% | +6.4% |
| 10-yr return (annualized) | +12.6% | +9.2% |
| Best quarter | +29.7% | +22.0% |
| Worst quarter | −28.9% | −21.0% |
| Net assets (fund) | $72.1M | $12.1M |
| Number of holdings | 70 | 69 |
| Portfolio turnover | 4% | 99% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RXL | HCPIX | Difference |
|---|---|---|---|
| 2024 | −2.7% | −1.4% | −1.3% |
| 2023 | −3.2% | −1.3% | −1.9% |
| 2022 | −15.1% | −10.6% | −4.5% |
| 2021 | +47.8% | +33.9% | +13.9% |
| 2020 | +19.2% | +16.9% | +2.4% |
| 2019 | +38.9% | +28.4% | +10.5% |
| 2018 | +5.4% | +5.0% | +0.4% |
| 2017 | +46.0% | +32.2% | +13.8% |
| 2016 | −8.9% | −6.5% | −2.4% |
Source: Fund prospectus bar charts
Holdings overlap
18 of RXL's top 25 holdings also appear in HCPIX's top 25.
| Holding | RXL | HCPIX |
|---|---|---|
| Eli Lilly & Co. | 12.67% | 11.83% |
| Johnson & Johnson | 7.86% | 8.03% |
| AbbVie, Inc. | 5.57% | 5.77% |
| UnitedHealth Group, Inc. | 4.98% | 4.90% |
| Merck & Co., Inc. | 4.26% | 4.19% |
| Thermo Fisher Scientific, Inc. | 2.68% | 2.78% |
| Amgen, Inc. | 2.62% | 2.71% |
| Gilead Sciences, Inc. | 2.41% | 2.10% |
| Intuitive Surgical, Inc. | 2.18% | 1.63% |
| Pfizer, Inc. | 2.15% | 1.86% |
| Abbott Laboratories | 2.15% | 2.40% |
| Bristol-Myers Squibb Co. | 1.68% | 1.74% |
| CVS Health Corp. | 1.67% | 1.73% |
| Danaher Corp. | 1.66% | 1.60% |
| Vertex Pharmaceuticals, Inc. | 1.64% | 1.57% |
Source: SEC Form N-PORT
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
HCPIX top 10
- Eli Lilly & Company — 11.83%
- Johnson & Johnson — 8.03%
- N/a — 6.45%
- Abbvie Inc — 5.77%
- N/a — 4.97%
- Unitedhealth Group Inc — 4.90%
- Merck & Company Inc — 4.19%
- N/a — 3.96%
- N/a — 3.96%
- N/a — 3.11%
FAQ
What is the difference between RXL and HCPIX?
Which is cheaper, RXL or HCPIX?
Should I own both RXL and HCPIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.